Targeted and cytotoxic therapy in coordinated sequence (TACTICS): Erlotinib, bevacizumab, and standard chemotherapy for nonsmall-cell lung cancer, a phase II trial

Clinical Lung Cancer

Volumn 13, Issue 2, 2012, Pages 123-128

  Cohen, Ezra E W ^a   Subramanian, Janakiraman ^b,c   Gao, Feng ^b   Szeto, Livia ^a   Kozloff, Mark ^a   Faoro, Leonardo ^a   Karrison, Theodore ^a   Salgia, Ravi ^a   Govindan, Ramaswamy ^b,c   Vokes, Everett E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MO   (United States)

Author keywords

Bevacizumab; EGFR TK mutation; Erlotinib; NSCLC advanced stage

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PACLITAXEL; PROTEIN TYROSINE KINASE;

ACNE; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BRAIN ISCHEMIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CYTOTOXICITY; DIARRHEA; DYSPNEA; FATIGUE; FEMALE; HEART DISEASE; HUMAN; INFECTION; LUNG ADENOCARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAINTENANCE DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PROTEINURIA; RASH; THROMBOCYTOPENIA; THROMBOSIS;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; QUINAZOLINES; SURVIVAL RATE;

EID: 84857433962     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.10.001     Document Type: Article

References (27)

1. A. Jemal, R. Siegel, E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. D.M. Parkin, F. Bray, J. Ferlay Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108 (Pubitemid 40372904)
3. J.H. Schiller, D. Harrington, C.P. Belani Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98 (Pubitemid 34438899)
4. F. Fossella, J.R. Pereira, J. von Pawel Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced NonSmall-Cell Lung Cancer: The TAX 326 Study Group Journal of Clinical Oncology 21 2003 3016 3024 (Pubitemid 46606280)
5. A. Sandler, R. Gray, M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550 (Pubitemid 44917502)
6. M. Reck, J. von Pawel, P. Zatloukal Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil J Clin Oncol 27 2009 1227 1234
7. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132 (Pubitemid 41058344)
8. G. Giaccone, R.S. Herbst, C. Manegold Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trialINTACT 1 J Clin Oncol 22 2004 777 784 (Pubitemid 41103588)
9. R.S. Herbst, G. Giaccone, J.H. Schiller Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trialINTACT 2 J Clin Oncol 22 2004 785 794 (Pubitemid 41103589)
10. R.S. Herbst, D. Prager, R. Hermann TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 2005 5892 5899
11. A. Sandler, R. Gray, J. Brahmer Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC# 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial-E4599 J Clin Oncol 23 2005 2s
12. A. Hirata, S. Ogawa, T. Kometani ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase Cancer Res 62 2002 2554 2560 (Pubitemid 34462734)
13. S.J. Kim, H. Uehara, T. Karashima Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice Clin Cancer Res 9 2003 1200 1210 (Pubitemid 36323730)
14. F. Ciardiello, R. Bianco, V. Damiano Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells Clin Cancer Res 6 2000 3739 3747
15. S. Guy, S. Ashton, G. Hughes Gefitinib (Iressa, ZD1839) enhances the activity of the novel vascular-targeting agent ZD6126 in human colorectal cancer and non-small cell lung cancer (NSCLC) xenograft models Clin Cancer Res 9 2003 6142S
16. R.S. Herbst, D.H. Johnson, E. Mininberg Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer J Clin Oncol 23 2005 2544 2555
17. P.N. Lara Jr., M.W. Redman, K. Kelly Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials J Clin Oncol 26 2008 463 467 (Pubitemid 351171700)
18. G. Giaccone, M. Gallegos Ruiz, T. Le Chevalier Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study Clin Cancer Res 12 2006 6049 6055 (Pubitemid 44703768)
19. A.-M.C. Dingemans, A.J. de Langen, V. van den Boogaart First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging Annals of Oncology 2010
20. K. Kelly, J. Crowley, P.A. Bunn Jr. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced nonsmall-cell lung cancer: a Southwest Oncology Group trial J Clin Oncol 19 2001 3210 3218 (Pubitemid 32591438)
21. T.T. Chen Optimal three-stage designs for phase II cancer clinical trials Stat Med 16 1997 2701 2711
22. J.H.R. Hainsworth A phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab (Avastin®) in combination with erlotinib (Tarceva®) compared with erlotinib alone for treatment of advanced non-small cell lung cancer after failure of standard first-line chemotherapy (BETA) Journal of Thoracic Oncology 3 2008 S263 S305
23. V.A. Miller, P. O'Connor, C. Soh A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) J Clin Oncol (Meeting Abstracts) 27 2009 LBA8002
24. R.S. Herbst, V.J. O'Neill, L. Fehrenbacher Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non Small-Cell Lung Cancer J Clin Oncol 25 2007 4743 4750 (Pubitemid 350086476)
25. T.S. Mok, Y.L. Wu, S. Thongprasert Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
26. M. Maemondo, A. Inoue, K. Kobayashi Gefitinib or Chemotherapy for Non Small-Cell Lung Cancer with Mutated EGFR New England Journal of Medicine 362 2010 2380 2388
27. P.A. Janne, X.F. Wang, M.A. Socinski Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 J Clin Oncol (Meeting Abstracts) 28 2010 7503